Becton, Dickinson and Company C (NYSE:BDX):
BD and Bard Receive Second Requests from FTC under HSR Act.
The company is trading up by 0.12% since yesterday’s close of $191.77.
The company also recently announced a dividend payable on Friday June 30th, 2017. The dividend payment will be $0.730 per share for the quarter which comes to $2.92 on an annualized basis. This dividend amount will represent a yeild of $1.52. The ex-dividend date will be Wednesday June 7th, 2017.
Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. It provides customer solutions that are focused on managing medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; managing drug delivery; aiding anesthesiology care; managing the diagnosis of infectious diseases and cancers; advancing cellular research and applications, and supporting the management of diabetes. The Company caters to markets, such as healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Business’s subsidiaries include Accuri Cytometers, Inc., BD Norge AS, CareFusion Canada 307 ULC, Vital Signs Hong Kong Limited and Dantor S.A..
It is currently trading at $192.00 which is just over $185.58, the stock’s 50 day moving average and marginally over the 200 day moving average of $178.53. The 50 day moving average was up $6.42 or +3.46% and the 200 day average went up $13.47 or +7.54%.
The P/E ratio is 31.89 and the market cap is 40.95B. In the last earnings report the EPS was $6.02 and is expected to be $9.44 for the current year with 213,305,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $2.37 with next year’s EPS anticipated to be $10.36.
A few brokerage analysts have released ratings on the company recently. On September 23 the stock rating was downgraded from “Neutral” to “Sell” with a current price target of $165.00 by analysts at Citigroup. Citigroup both downgraded the stock and raised the price target on September 23 changing the price target from $146.00 to $165.00 and altering the rating from “Neutral” to “Sell”.
On February 11, 2016 the stock rating was set at “Buy” in a report from Deutsche Bank which is up from the previous “Hold” rating. On February 4 Citigroup held the stock rating at “Neutral” but moved down the price target from $153.00 to $146.00.
On January 6 the company was changed to a “Hold” by Evercore ISI Group a cut from the previous “Buy” rating. On January 4 the company was downgraded to “Equal-weight” from “Overweight” in a report issued by Morgan Stanley.